Skip to content
Clinical Trials – home
NorwayBack to Norway

Clinical trials in Hønefoss – page 3

606 clinical trials in Hønefoss, Norway. Every trial is listed in the EU Clinical Trials Register and updated daily.

NorwayOur site in NorwayKliniske-Studier.no(opens in a new tab)
Hønefoss at a glance
606
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

606 trials in Hønefoss

Open in trial search

Coeliac disease

Recruiting

Study on ZED1227 for Improving Symptoms in Celiac Disease Patients on a Gluten-Free Diet

Investigational
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Vilagletistat
  • Sponsor:Dr. Falk Pharma GmbH

Study of Dostarlimab After Chemoradiation for Adults with Advanced Unresected Head and Neck Cancer

Registered drug
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Dostarlimab
  • Sponsor:Glaxosmithkline Research & Development Limited

Crohn's disease

Recruiting

Study on the Effects of Zasocitinib for Patients with Moderate to Severe Crohn's Disease

Investigational
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Zasocitinib
  • Sponsor:Takeda Development Center Americas Inc.

Study on the Long-term Safety and Efficacy of Pembrolizumab and Lenvatinib for Patients with Advanced Tumors

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Favezelimab
  • Sponsor:Merck Sharp & Dohme LLC

Testing inotuzumab ozogamicin and blinatumomab with drug combination for children with relapsed precursor B-cell acute lymphoblastic leukemia

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:0–17 years · 18–64 years
  • Substances:Blinatumomab
  • Sponsor:Charite Universitaetsmedizin Berlin KöR

Study on the Safety and Effectiveness of EIK1001 and Pembrolizumab for Patients with Advanced Melanoma

Registered drug
Countries:NorwayNorway
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Eikon Therapeutics Inc.

Study of NTLA-2001 for Patients with Transthyretin Amyloidosis and Heart Disease

Registered drug
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone
  • Sponsor:Intellia Therapeutics Inc.

Phase 3 Study of GSK6042981 versus Imatinib in Adults with Previously Untreated Metastatic or Unresectable Gastrointestinal Stromal Tumors (GIST)

InvestigationalNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Imatinib Mesilate
  • Sponsor:Glaxosmithkline Research & Development Limited

Comparing Daraxonrasib Alone or Combined with Gemcitabine and Paclitaxel Albumin‑Bound vs Standard Chemotherapy in Patients with Metastatic Pancreatic Adenocarcinoma

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Daraxonrasib
  • Sponsor:Revolution Medicines Inc.

HIV infection

Recruiting

Durable HIV-1 control with 10-1074-LS, 3BNC117-LS and nivolumab in adults on ART: a randomized double‑blind placebo‑controlled trial

Registered drug
Countries:NorwayNorway
  • Participants:18–64 years
  • Substances:Nivolumab
  • Sponsor:Region Midtjylland

Ifinatamab deruxtecan in Patients With Advanced Esophageal Squamous Cell Carcinoma

InvestigationalNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Ifinatamab Deruxtecan
  • Sponsor:Merck Sharp & Dohme LLC

Anaemia+1

Recruiting

A Phase 3 Study of Elritercept Versus Epoetin Alfa in ESA‑Naïve Adults with Lower‑Risk Myelodysplastic Syndrome Requiring Red Blood Cell Transfusions

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Elritercept
  • Sponsor:Takeda Development Center Americas Inc.

Other cities in Norway

The busiest research cities in the country

All 53 cities in Norway

Clinical research in Hønefoss

What the registry says about research in the country

01 Musculoskeletal Diseases

In Hønefoss, researchers are evaluating non‑pharmacologic and medication approaches for acute neck pain. The study compares chiropractic spinal manipulative therapy with standard use of NSAIDs to determine which method best reduces pain intensity during the treatment period.

  • Comparative effectiveness of manual therapy versus medication
  • Measurement of pain intensity and functional recovery
  • Patient‑reported outcome measures
  • Safety and feasibility of combined treatment strategies

Findings aim to guide clinicians in selecting optimal first‑line interventions for neck pain, potentially improving recovery speed and patient satisfaction.

02 Bacterial Infections and Mycoses

Clinical investigators are studying patients with suspected community‑acquired sepsis to assess whether a regimen of narrow spectrum β‑lactam antibiotics together with an aminoglycoside is safe and non‑inferior to standard broad spectrum antibiotics. The goal is to refine early treatment choices while minimizing unnecessary broad‑spectrum exposure.

  • Early antibiotic stewardship in severe infections
  • Safety profiling of combination therapy
  • Efficacy comparison with broad‑spectrum regimens
  • Impact on patient outcomes and hospital stay

Results could support more targeted antibiotic use, preserving effectiveness of broad‑spectrum agents and reducing resistance development.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.